pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Big Pharma · news · pharmadog
← back to Big Pharma
News · Big Pharma
308
stories
13d
Faeth’s phase 2 data power oral combo forward in cancer targeted by ADC heavyweights
fiercebiotech
13d
Merck abandons Sutro-partnered IL-2 drug in ‘routine pipeline prioritization’
fiercebiotech
13d
T-time: British biotech pours $133M into the pot for bispecifics
biospace
13d
Coveted metabolic gem Rhythm reportedly gets $10B offer from AstraZeneca
biospace
13d
AHA: Novartis’ Lp(a) drug shows zero benefit, casting shadow over Amgen and Lilly programs
fiercebiotech
14d
China climbed biotech's worry list, while Big Pharma kept shopping
endpoints
14d
With MFN now embedded in pharma, execs see little impact from Democrats’ blue wave
biospace
14d
Boehringer returns to Sino Biopharma in $7.4B deal for preclinical TCEs, ADCs
fiercebiotech
15d
AbbVie pens $1.4B deal for deprioritized IBD drug from Nxera
fiercebiotech
15d
Sanofi scraps STAT6 degrader from Nurix just 2 months after entering clinic
fiercebiotech
15d
6 potential blockbusters that could pave China’s path to 2030 ambitions
biospace
15d
Novo’s CEO still looking for deals to ‘close some of the gaps,’ as misfires hit profits
fiercebiotech
15d
Servier’s $1.6B muscular dystrophy bet on Edgewise delivers quick-fire pivotal failure
fiercebiotech
15d
T-Therapeutics raises $133M series B for bispecific pipeline with Big Pharma backers in tow
fiercebiotech
15d
Novartis puts $772M BioArctic deal on ice, skates away from brain-delivery alliance
biospace
15d
AbbVie abandons phase 2 solid tumor drug over ‘limited benefit’
fiercebiotech
15d
Pfizer pares back obesity pipeline, drops phase 2-stage lung disease candidate
fiercebiotech
16d
AbbVie invests £120M in UK, including expanded R&D site
fiercebiotech
16d
BioArctic left out in the cold as Novartis walks away from $800M neuro collab
fiercebiotech
16d
Cell therapy investment grows as safety events rankle Big Pharma's CAR T autoimmune push
biospace
16d
Teva ends trial of one of its original line-up of innovative meds over futility
fiercebiotech
17d
Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdict
biospace
19d
AbbVie’s Q3 beat should keep ‘train rolling’ as company eyes bolt-on deals
biospace
19d
AstraZeneca employs $1.5B cost savings to reinvest back into growth
biospace
19d
Regeneron achieves ‘clean sweep’ in Q3 with myriad pipeline catalysts on deck
biospace
20d
AstraZeneca cuts early-phase prostate cancer pipeline
fiercebiotech
20d
Sanofi considering ‘moonshot’ treatments as M&A targets to survive Dupixent patent cliff
fiercebiotech
20d
Lilly’s guidance has jumped by $10B as GLP-1 sales keep blowing past expectations
biospace
20d
BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat
biospace
20d
Eli Lilly scraps phase 2 Alzheimer's program after drug falls short of expectations
fiercebiotech
← prev
page 2 of 11
next →